Artikkelit - Selaus asiasanan mukaan "cancer"
Viitteet 1-2 / 2
-
Are products with an orphan designation for oncology indications different from products for other rare indications? : A retrospective analysis of European orphan designations granted between 2002-2012
Orphannet Journal of Rare Disease : 1 (BioMed Central, 16.02.2017)Background: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare ... -
Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide : A randomized comparison
Transfusion : 6 (Blackwell Publishing, 01.06.2016)
